Ligand Pharmaceuticals Expected to Issue Conservative 2026 Outlook at Upcoming Investor Day, RBC Says

MT Newswires Live

16小時前

Ligand Pharmaceuticals (LGND) is expected to issue conservative 2026 guidance at its upcoming investor day, with updates to its royalty outlook anchored by Zelsuvmi and the upcoming Filspari regulatory decision, RBC Capital markets said in a note Tuesday.

RBC expects 2026 adjusted core EPS of $7.91 and revenue of $251 million.

The company's recent launch of Zelsuvmi has shown "strong momentum" with IQVIA (IQV) monthly prescriptions rising from 113 in July to 1,291 in October, RBC noted.

Filspari is a major near-term catalyst with an upcoming regulatory decision in January 2026 and RBC estimates the therapy could contribute roughly $148 million in royalty receipts by 2030.

The company's investor day is scheduled on Dec. 9.

RBC reiterated its outperform rating on Ligand Pharmaceuticals and set a $234 price target.

Price: 206.29, Change: -0.60, Percent Change: -0.29

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2586606477"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586606477\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586606477?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-26 00:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586606477","market":"sh","top_or_hot":-1,"title":"Ligand Pharmaceuticals Expected to Issue Conservative 2026 Outlook at Upcoming Investor Day, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Ligand Pharmaceuticals (LGND) is expected to issue conservative 2026 guidance at its upcoming investor day, with updates to its royalty outlook anchored by Zelsuvmi and the upcoming Filspari regulatory decision, RBC Capital markets said in a note Tuesday.</p><p>RBC expects 2026 adjusted core EPS of $7.91 and revenue of $251 million.</p><p>The company's recent launch of Zelsuvmi has shown \"strong momentum\" with IQVIA (IQV) monthly prescriptions rising from 113 in July to 1,291 in October, RBC noted.</p><p>Filspari is a major near-term catalyst with an upcoming regulatory decision in January 2026 and RBC estimates the therapy could contribute roughly $148 million in royalty receipts by 2030.</p><p>The company's investor day is scheduled on Dec. 9.</p><p>RBC reiterated its outperform rating on Ligand Pharmaceuticals and set a $234 price target.</p><p>Price: 206.29, Change: -0.60, Percent Change: -0.29</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ligand Pharmaceuticals Expected to Issue Conservative 2026 Outlook at Upcoming Investor Day, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLigand Pharmaceuticals Expected to Issue Conservative 2026 Outlook at Upcoming Investor Day, RBC Says\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-11-26 00:19</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Ligand Pharmaceuticals (LGND) is expected to issue conservative 2026 guidance at its upcoming investor day, with updates to its royalty outlook anchored by Zelsuvmi and the upcoming Filspari regulatory decision, RBC Capital markets said in a note Tuesday.</p><p>RBC expects 2026 adjusted core EPS of $7.91 and revenue of $251 million.</p><p>The company's recent launch of Zelsuvmi has shown \"strong momentum\" with IQVIA (IQV) monthly prescriptions rising from 113 in July to 1,291 in October, RBC noted.</p><p>Filspari is a major near-term catalyst with an upcoming regulatory decision in January 2026 and RBC estimates the therapy could contribute roughly $148 million in royalty receipts by 2030.</p><p>The company's investor day is scheduled on Dec. 9.</p><p>RBC reiterated its outperform rating on Ligand Pharmaceuticals and set a $234 price target.</p><p>Price: 206.29, Change: -0.60, Percent Change: -0.29</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0477156797.USD","symbol_name":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2586606477","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586606477","pubTimestamp":1764087588,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ligand Pharmaceuticals  is expected to issue conservative 2026 guidance at its upcoming investor day, with updates to its royalty outlook anchored by Zelsuvmi and the upcoming Filspari regulatory decision, RBC Capital markets said in a note Tuesday.RBC expects 2026 adjusted core EPS of $7.91 and revenue of $251 million.The company's recent launch of Zelsuvmi has shown \"strong momentum\" with IQVIA  monthly prescriptions rising from 113 in July to 1,291 in October, RBC noted.Filspari is a major near-term catalyst with an upcoming regulatory decision in January 2026 and RBC estimates the therapy could contribute roughly $148 million in royalty receipts by 2030.The company's investor day is scheduled on Dec. 9.RBC reiterated its outperform rating on Ligand Pharmaceuticals and set a $234 price target.Price: 206.29, Change: -0.60, Percent Change: -0.29","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0566484027.USD":"安本美国小盘成长股","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","BK4007":"制药","BK4588":"碎股","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","LGND":"Ligand Pharmaceuticals Inc.","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","BK4121":"生命科学工具和服务","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","BK4139":"生物科技","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","IQV":"艾昆纬","BK4530":"医药外包概念","BK4585":"ETF&股票定投概念","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC"},"translate_title":"加拿大皇家银行表示，Ligand Pharmaceuticals预计将在即将到来的投资者日发布保守的2026年展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGND":1.5,"IQV":1},"content_text":"Ligand Pharmaceuticals (LGND) is expected to issue conservative 2026 guidance at its upcoming investor day, with updates to its royalty outlook anchored by Zelsuvmi and the upcoming Filspari regulatory decision, RBC Capital markets said in a note Tuesday.RBC expects 2026 adjusted core EPS of $7.91 and revenue of $251 million.The company's recent launch of Zelsuvmi has shown \"strong momentum\" with IQVIA (IQV) monthly prescriptions rising from 113 in July to 1,291 in October, RBC noted.Filspari is a major near-term catalyst with an upcoming regulatory decision in January 2026 and RBC estimates the therapy could contribute roughly $148 million in royalty receipts by 2030.The company's investor day is scheduled on Dec. 9.RBC reiterated its outperform rating on Ligand Pharmaceuticals and set a $234 price target.Price: 206.29, Change: -0.60, Percent Change: -0.29","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}